Blood Group Typing Market Assessment, By Product [Consumables, Kits, Instruments], By Test Type [ABO Tests, Antigen Typing, Antibody Screening, Cross-Matching Tests, HLA Typing], By Technique [Serological Tests, Molecular Tests], By End-user [Hospitals, B

Blood Group Typing Market Assessment, By Product [Consumables, Kits, Instruments], By Test Type [ABO Tests, Antigen Typing, Antibody Screening, Cross-Matching Tests, HLA Typing], By Technique [Serological Tests, Molecular Tests], By End-user [Hospitals, Blood Banks, Independent Laboratories], By Region, Opportunities and Forecast, 2017-2031F

Global blood group typing market is projected to witness a CAGR of 9.09% during the forecast period 2024-2031, growing from USD 2107 million in 2023 to USD 4226.14 million in 2031. The market for products associated with blood group typing is anticipated to grow exponentially in the forecast period owing to rising awareness about blood transfusions and increasing demand for blood testing.

Blood group typing involves tests to identify the blood group, antigen, and antibody present in an individual. The market for products used for blood group typing, such as instruments, kits, reagents, and consumables, is driven by several growing factors, such as increasing blood donations and transfusion procedures across the globe and the involvement of automation in the process. The market is anticipated to register significant growth due to novel technologies used for such procedures as HLA typing, inculcation of artificial intelligence, heightened demand for high-throughput instruments to work at a faster pace, and many more. The efforts of market leaders, such as strategic product launches, approvals, and other market tactics are anticipated to help in further growth of the market in the forecast period.

For instance, in April 2024, Grifols, S.A. launched its leading blood-typing technology, the automated Erytra Eflexis, in the Chinese market after regulatory approval. The system uses ""load-and-go"" automation to rapidly perform complex blood-typing analytics and is designed to enhance pretransfusion compatibility testing. Using Grifols' DG gel technology confirms blood-group compatibility through the presence or absence of different red-blood antigens and antibodies. The Erytra Eflexis optimizes workflow efficiency and can be tailored to various lab configurations and processing needs, providing reliable, timely results.

Rising Blood Transfusion and Donation Procedures Across the Globe

The global increase in blood transfusion and donation procedures significantly impacts the demand for blood group typing products. As the number of blood donations rises, so does the need for effective blood group typing products. Blood group typing is essential for ensuring safe and compatible transfusions, reducing the risk of adverse reactions and infections. The demand for closely matched blood types is particularly high among patients requiring regular transfusions, such as those with thalassemia or sickle cell anemia. This demand necessitates a robust system for blood typing to ensure that the right blood type is available when needed. The demographic profile of blood donors is also changing; with increasing awareness of blood donations, more people are donating blood on a regular basis. All these factors reflect a promising future for the blood group typing market. For instance, as per data published by the Centers for Disease Control and Prevention in February 2024, there are approximately 7 million blood donors, and more than 14 million units of blood transfused annually in the United States.

Shift Towards Automated Blood Group Typing Techniques

The shift towards automated blood group typing techniques is reshaping the demand for blood group typing products, driven primarily by the adoption of molecular typing methods. These methods, including PCR, microarray, and next-generation sequencing, are becoming increasingly prevalent due to their ability to provide highly accurate and rapid results, even in complex cases such as recently transfused patients or those with autoantibodies. Automated molecular techniques offer significant advantages over traditional serological methods, such as they can detect rare, weak, and variant blood group antigens, providing faster turnaround times and delivering increased sensitivity and specificity. For instance, in June 2024, Innobiochips launched Omnys, a cutting-edge automated blood grouping and testing system designed to enhance lab productivity and reduce environmental impact. Omnys utilizes exclusive technologies to enable multiplex testing with unparalleled precision, reliability, and efficiency using minimal sample volumes. It can perform up to 10 tests per well, offering ultimate blood compatibility and expanded sample characterization without additional costs. Such innovation in the market is anticipated to drive notable growth.

Rapid Growth of the HLA Typing Segment

The HLA typing segment is anticipated to register the highest CAGR in the blood group typing market. The rapid growth of HLA typing has transformed transplant and transfusion procedures, evolving from serological methods to advanced molecular techniques like sequence-based typing. While distinct from blood group typing, advancements in HLA typing have positively influenced blood group methods. Molecular techniques such as PCR have improved the reliability of blood group antigen identification, particularly for patients with rare types or specific antibodies. The strategic product launches by players in recent times for catering HLA typing segment further enhance its market share. For instance, in April 2023, Metropolis Healthcare Limited introduced the ""NextGen HLA"" Typing Test, which utilizes the advanced molecular technology called 'Next Generation Sequencing (NGS)'. The NextGen HLA Typing test is a highly detailed molecular test performed for Hematopoietic Stem Cell Transplant (HSCT) and solid organ transplantation. This test helps in identifying a suitable donor for bone marrow, cord blood, or organ transplant by analyzing the Human Leukocyte Antigen (HLA) genes inherited from the parents.

North America Dominates Blood Group Typing Market

North America is anticipated to account for the largest share of the blood group typing market in 2023, driven by a robust healthcare infrastructure and significant investments in research and development (R&D) of innovative diagnostic techniques. The presence of a large number of blood banks and laboratories, a high number of transfusions performed, and favorable reimbursement scenarios in the region support the robust growth of the market. For instance, according to the American Red Cross Society, nearly 16 million blood components are transfused each year in the United States. Apart from that, the presence of several major players in the United States market further boosts the market share. Increased blood donation awareness collectively positions North America as the dominant region in consuming blood group typing products. This trend is expected to continue, with the market projected to grow significantly in the coming years.

Future Market Scenario (2024-2031F)

High-throughput DNA-based genotyping techniques are revolutionizing the blood group typing market. It offers several advantages over traditional serological methods for efficiently testing blood groups. DNA genotyping allows for the testing of thousands of samples per run, making it highly scalable for screening large donor populations, which is much more efficient than the laborious and expensive process of serologically typing large donor populations. High-throughput genotyping platforms like DNA arrays enable rapid, comprehensive, and cost-effective blood group testing of large donor populations, facilitating the identification of rare phenotypes and better matching between recipients and donors to improve transfusion safety and efficiency. For instance, in May 2024, Thermo Fisher Scientific Inc. introduced the Applied Biosystems Axiom BloodGenomiX Array and Software, a solution for precise blood genotyping in clinical research. The new array detects extended and rare blood groups, tissue (HLA), and platelet (HPA) types in a single, high-throughput assay, supporting advancements in donor blood matching for extended phenotypes.

Key Players Landscape and Outlook

Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Merck KGaA, Beckman Coulter, Inc. (Danaher Corporation), Grifols, S.A., Agena Bioscience, Inc., Illumina Inc., QIAGEN N.V., Werfen, S.A., QuidelOrtho Corporation are some of the leading market players active in global blood group typing market. Significant market activities reported in recent times include distribution agreements and acquisitions alongside several product launches. The market players are actively showing interest in market developments to enhance the growth rate.

In June 2023, AliveDx (formerly Quotient) and TransMedics Group, Inc. signed a distribution agreement, allowing TransMedics to distribute Alba by Quotient and MosaiQ in five Southeast Asian countries. This partnership reinforces Quotient's commitment to expanding its geographical presence and enhancing regional patient care. TransMedics, a leader in medical technology in Southeast Asia, will be distributing these products as part of their regional operations.

In March 2023, Werfen, S.A. completed the acquisition of Immucor, Inc., a United States-based company in the diagnostics sector. The acquisition was priced at USD 2 billion and will expand Werfen's presence in the specialized diagnostics market, including the blood group type segment. The combined revenues are expected to exceed USD 2.45 billion, and the company is expected to have seven technology centers and employ more than 7,000 people worldwide following this acquisition.